Revolutionizing

aortic care for life.

Investor Presentation
May 4, 2017
Safe Harbor

Forward-Looking Statements
This presentation includes statements that may be forward-looking statements. The words believe, expect, anticipate,
project, forecast and similar expressions, among others, generally identify forward-looking statements. Forward-looking
statements used in this presentation include those with respect to revenue growth and path to profitability, new product
launches, market opportunity and growth, timeline for Nellix PMA and other regulatory approvals, anticipated product
labeling, and revenue guidance for 2017. Endologix cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such
risks and uncertainties include, but are not limited to, competition from other products, changes to laws and regulations
applicable to our industry, progress of our ongoing clinical trials, clinical trial results, decisions and the timing of decisions of
regulatory authorities regarding our products and potential future products, delays in new product launches, market
acceptance of our products, and risks relating to foreign currency fluctuations. Additional information about the factors that
may affect Endologixs operations and results is set forth in Endologixs annual and periodic reports filed with the Securities
and Exchange Commission (the SEC). Endologix undertakes no obligation to release publicly any revisions to forward-
looking statements as a result of subsequent events or developments, except as required by law.

In the U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and currently
not approved in any market

2
Revolutionizing Aortic Care for Life

Unmatched AAA Innovation leader with broadest

Technology: product offering and indications
EVAR + EVAS Significant clinical evidence

Significant Revenue Multiple new product launches

Growth Potential Global sales force + distribution network

Clear Path to Significant merger synergies

Profitability Operating leverage
3
Most Comprehensive AAA Product Line in the World

to provide the best device for each patient

4
Global Aortic Market Opportunity Reaching $4.8B by 2021

Traditional AAA Complex AAA Thoracic

$1.6B $1.2B $1.2B

Current $0.3 $0.8

Market
Opportunity $0.6 $0.6
$4.0B $1.3 $0.4
81% endo 31% endo 50% endo
penetrated penetrated penetrated
Endo Treated Open Opportunity Endo Treated Open Opportunity Endo Treated Open Opportunity

Projected $1.4B $1.5B

Market
Opportunity $1.9B
$4.8B 4%
9% 8%
Endo
Endo
(by 2021) Endo 86% endo
CAGR
41% endo CAGR 58% endo
CAGR penetrated penetrated penetrated

5
TREAT MORE PATIENTS
MORE EFFECTIVELY

Standard Anatomy

Aortic Neck Thrombus-Laden Neck

Challenges Calcific Neck
Reverse Taper Necks
Infrarenal placement

Access Small Access Vessels

Challenges Tortuous/Calcified
Preservation of Bifurcation

Aneurysm Narrow Distal Aorta

In the U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix
Characteristics Patent IMA/Lumbars
ChEVAS are investigational devices and currently not approved in any market.
Short Common Iliac
Concomitant Iliac Aneurysm
AFX/AFX2 A Proven EVAR Solution

Preserves native bifurcation for reliable, stable repair

PERFORMANCE IN CHALLENGING ANATOMIES

RESULTS FROM A 167 PATIENT
MULTI CENTER STUDY ~50% of Patients had Challenging Anatomies
Low endoleak rates, even in Challenging
ActiveSeal extends the seal zones for Anatomies
a durable seal
Type I Endoleak
Extended
Seal Zone1
Durable
Seal1
2.4%
5.7 mm 96% Type II Endoleak
Beyond margin Sac regression or
of neck stabilization
5.5%
1: Arthurs et al. Endograft Apposition at the Proximal Aortic Neck Predicts Aneurysm Sac Regression. Presented at the Western Vascular 2014 Annual Meeting. September, 2014. Avg patient follow-up 10 months

CAUTION Endologix products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding
product availability. Prior to use, refer to the Instructions for Use for complete and specific indications, contraindications, all warnings and precautions. Rx only. 7
Nellix 2-Year Clinical Results EVAS Global Registry

Freedom from
Freedom from
Aneurysm-Related
Persistent Endoleaks
Mortality

98% 97%
37 %
complex Secondary Freedom from
Interventions for Cardiovascular
Type II Endoleaks Mortality

0% 99%
These data continue to support positive outcomes in a real world patient population that
had no screening or anatomical restrictions at enrollment, and constitute the broadest
range of aortic anatomies for any prospective endovascular AAA study.

In the U.S., Nellix is limited to investigational use only. 8

Preliminary 2-Year Nellix IDE Results with New IFU
Freedom from T1a, expansion, migration

New IFU

Original IFU
95.6%
p=0.0024
84.7% Freedom from T1a
Endoleak, Sac Expansion
and Migration at 2-Years

Results as of Feb 2, 2017

Comparable EVAR IDE

Results are 91.5%

CAUTION: The Nellix EndoVascular Aneurysm Sealing System is an investigational

device in the United States ,limited by federal (or United States) law to investigational use only.
9
Roadmap to Nellix Gen 1 PMA Approval*

2017 2018
Q1 Q2 Q3 Q4 Q1 Q2

SUBMIT 2-YEAR ChEVAS PANEL PMA

RESULTS TO FDA IDE MEETING APPROVAL

FDA Review

*Estimated milestones and approval based upon Gen1 device and current timelines and assumptions
In the U.S., Nellix is limited to investigational use only. 10
Ovation Clinical Results - LIFE Registry

Fast Track EVAR with Ovation is the safest, least invasive path to
faster discharge, fewer readmissions and lower hospital costs
30-day results Ovation LIFE EVAR Traditional EVAR
MAE 0.5% 3-4%
1
Not device/procedure related

Procedure Time
min 84 110
ICU
days 0 1.4 2

LOS
days 1.2 2.9 2

1.6% 8%
3,4
30-day Readmission

1. 30d MAE rates for commercially available EVAR devices per US FDA SSED reports and post market global registries. Data on file. 2. Premier EVAR. 3. Chen SL et al. Perioperative Risk Factors for Readmission
11
Following EVAR. Presented at SCVS, 2016. 4. Gupta PK, et al. Unplanned readmissions after vascular surgery. J Vasc Surg 2014;59:473-82.
Ovation Alto and Nellix ChEVAS Expand Treatment to Complex AAA Patients

Pipeline products to address

COMPLEX AAA
Nellix
ChEVAS
Ovation
Alto

Expands access to $1.2B

market opportunity

*Based on anticipated FDA Labeled Indications. Derived from M2S Database of 43,000 AAA CT Scans. Represents estimated treatment applicability with Ovation and Nellix. In the
U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and currently not approved in any market. 12
Patient Applicability and Market Opportunity

Total ELGX
TRADITIONAL 40% 55% 69% 80% 80%
TOTAL
ELGX

Total ELGX $2.1B

COMPLEX 50% 26% 63%

MARKET TOTAL MARKET

$0.6B $0.6B $0.9B $1.1B $1.6B $2.8B
OPPORTUNITY

*Based on existing and estimated FDA Labeled Indications. Derived from M2S Database of 43,000 AAA CT Scans, other sources and company estimates. Represents treatment applicability based upon
company estimates, anticipated labeling and currently available information. In the U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and not
currently approved in any market. 1313
Broadest Patient Applicability

77%
19% ChEVAS & Alto

58% Current products

52%
47% 49%

~% Patients within FDA IFU*

Endologix
Gore Cook Medtronic
*Based on existing and estimated FDA Labeled Indications. Derived from M2S Database of 43,000 AAA CT Scans, other sources and company estimates. Represents treatment
applicability with AFX, Ovation and Nellix 3.5/Gen2, based upon company estimates, anticipated labeling and currently available information. In the U.S. Nellix is limited to
investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices and not currently approved in any market. 14
New Product Pipeline*

2017 2018 2019 2020

Arg/ US
AP US Japan China
Brazil Gen2

EU LA AP US

EU Japan Arg/ China

Brazil

Arg/
AP LA Japan
Brazil

EU AP US LA Japan

AP LA
Asia US EU Latin
Pacific America

*Estimated regulatory approvals. Assumes Panel for Nellix Gen 1 in U.S.

and no clinical study required for Ovation Alto CE Mark 15
2017 Growth Drivers and Priorities

PRODUCT LAUNCHES CLINICAL & REGULATORY R&D

ELEVATE IDE
EVAS
Nellix 2-Year Results NextGen

LUCY
LEOPARD
ELEVATE2 Thoracic
ChEVAS IDE
Sales Force Training Complete

*Based on current anticipated regulatory timelines and approvals. In the U.S. Nellix is limited to investigational use only. Ovation Alto and Nellix ChEVAS are investigational devices
and currently not approved in any market 16
2017 Sales Guidance

$103M - $109M FY 2017 Revenue

$47M - $48M $193-200M
$43M
KEY ASSUMPTIONS
1H sales disruption due to
previous AFX CE and
manufacturing issues
Sequential quarterly sales
growth expected as AFX
issues resolve, Ovation
growth in U.S. and Launch of
Alto in Europe

Q1 Actual Q2 Q3 Q4 OPEX target $170M-$175M

17
Summary

Innovation leader in $4 billion current market

opportunity
Traditional and Complex AAAs + Thoracic
Broadest portfolio of devices and indications
Significant clinical evidence
Growth drivers for 2017
Ovation Alto and Nellix ChEVAS in Europe
Ovation clinical results and adoption in U.S.
AFX2 in Japan
Experienced global sales and clinical professionals
Excellent financial profile
Operating leverage
Clear path to profitability
18